Similar mechanisms have been called upon concerning the development of IFIs in COVID-19 patients, together with the use of corticosteroids and immunomodulatory agents as a part of therapy and with the absolute count and CD4+ lymphopenia associated with COVID-19, whose levels correlate with disease severity and poor prognosis [20,21,22]. The gene discussed is CD4; the disease is COVID-19.